Core Viewpoint - Duori Pharmaceutical reported a significant decline in financial performance for the year 2024, with a notable drop in revenue and net profit compared to the previous year [1][2]. Financial Performance - The company achieved an operating revenue of 240.63 million yuan in 2024, representing a year-on-year decrease of 28.02% from 334.30 million yuan in 2023 [2]. - The net profit attributable to shareholders was -62.67 million yuan, a drastic decline of 432.44% compared to a profit of 18.85 million yuan in the previous year [2]. - The net profit after deducting non-recurring gains and losses was -66.45 million yuan, down 1,365.60% from 5.25 million yuan in 2023 [2]. - The net cash flow from operating activities was -67.18 million yuan, a decline of 641.19% from a positive cash flow of 12.41 million yuan in the previous year [2]. Dividend Distribution - The profit distribution plan for 2024 includes no cash dividends, no bonus shares, and no capital increase from reserves [2]. Company Background - Duori Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on September 29, 2021, with an initial public offering of 20 million shares, accounting for 25% of the total share capital post-IPO [3]. - The IPO price was set at 27.27 yuan per share, with the stock reaching a peak of 54.55 yuan on its first trading day, but it is currently in a state of decline [3]. - The total funds raised amounted to 545 million yuan, with a net amount of 482 million yuan after deducting issuance costs [3]. - The funds were intended for various projects, including the production of sodium acetate injection, new product development, and the establishment of a headquarters and R&D center in Tibet [3].
多瑞医药2024转亏 2021上市即巅峰中信证券保荐